

Donald J. Hillebrand, MD.

GI-Hepatology, Transplant Hepatology Medical Director, UnityPoint Health Center for Liver Disease Adjunct Assistant Professor Internal Medicine DMU

University of New Mexico Hepatitis C ECHO

ORIGINAL ARTICLI

Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care
Providers

Sanjeev Arors, M.D., Karla Thornton, M.D., Glen Murata, M.D., Paulina Deming, Pharm.D., Summers Kalishman, Ph.D., Denise Dion, Ph.D., Brooke Parish, M.D., Thomas
Burke, B.S., Wesley Pak, M.B.A., Jeffrey Dunkelberg, M.D., Martin Kistin, M.D., John Brown, M.A., et al.

June 9, 2011

N Engl J Med 2011; 364:2199-2207

Conclusions

 The results of this study show that the ECHO model is an effective way to treat HCV infection in underserved communities.
 Implementation of this model would allow other states and nations to treat a greater number of patients infected with HCV than they are currently able to treat.

(Funded by the Agency for Healthcare Research and Quality and others.)







- Statewide HCV ECHO for its Community Health Care Centers (CHCs) to develop knowledge and capacity among CHC clinicians through ongoing tele-mentoring and education.
 - University of New Mexico model
 - Sanjeev Arora, M.D.



- leverage scarce resources;
- share best practices to reduce disparities;
- use case-based learning to master complexity; and monitor outcomes using a web-based database.



ECHO HUB







• HCV ECHO is a telementoring program that uses videoconferencing technology (Zoom) to combine MAT didactic presentations with interactive and practical **HCV** case presentations from participants.

 https://www.youtube.com/u ser/ProjectECHOUNM











Meet the Hepatitis C ECHO Team at the Iowa PCA



Donald Hillebrand, M.D. is the Medical Director of UnityPoint Health Center for Liver Disease in Des Moines, towa, with Outreach Clinics in Ceder Rapids, Grinnell, Oscella, Nevada, Boone, and Fort Dodge. He is board certified in Giffepatology and Transplant Hepatology by the American Board of Internal Medicine. Dr. Hillebrand has been managing Liver, Intestinal and Multivisceral Transplantation at Indiana University Health (Ill Health) and Associate Professor of Clinical Medicine at the Indiana University School of Medicine. Dr. Hillebrand is the lead hepatology expert for this ECHO program.



Megan Srinivas, MD, MPH is a primary care provider with Community Health Certer of Fort Dodge in Fort Dodge, Iowa, She is a board certified in infectious disease by the American Board of Internal Medicine. Dr. Srinivas received both her undergraduate and MPH degrees from Harvard, her medical degree from University of Iowa's Carver College of Medicine, and completed her residency training from Johns Hopkins. She will serve as an infectious disease expert for HCV ECHO program.



Steven Donnelly, PharmD, is a specialty pharmacist at Community, A Walgreens Specialty Pharmacy in Des Moines, lowa. Dr. Donnelly is the lead pharmacy expert for the HCV ECHO program.



Mark Hillenbrand, LICSW, conducts psychotherapy with individuals, couples, families, and groups at his private practice, Authentic Freedem, in Des Moines, lowa. He is trained in self-psychology, object relations, and pational counseling. Mark specialises in assisting individuals diagnosed with chronic and traumatic illness, to identify and take steps in continuing their journey of leading health lives. Mark has extensive experience in working with individuals diagnosed with HIV/AIDS, HCV, Huntington's Disease and other significant health diagnoses.



Madisia Sprenger, MS, IAADC, is currently the Coordinator of Turning Point Treatment Center, including Medication Assisted Treatment Services, and is the Clinical Opioid Lead for MercyOne Dubuque Medical Center. She holds a Master of Science degree in Clinical Psychology and an International Advanced Alcohol and Drug Courselor Certification, For the past three years, Malissa has facilitated an Opioid Response Team with city, country, state, and federal representation. Molissa is Vice President of the lows Board of Certification Board of Directors and Chair of the MercyOne System Opioid Task Force.



Julie Baker, MPR. CHCEF, is the Director of Preventive Services at the lowa PCA providing training, technical assistance, and program development focused around HIV, Hepatitis and STDs, and related areas. Julie serves as the ECHO Program Coordinator for the HCV ECHO program.



Gagandeep Lamba, MA, MS, MBA, CSM, is a Performance Improvement Manager at Iowa PCA providing training, technical assistance, and quality improvement support to Iowa's health centers. Gagan will assist with the ECHO program coordination.



Estelle Montgomety, MPA, is an Emerging Programs Project Manager at lowa PCA. She has an extensive background in healthcare public policy, research, and implementation. Estelle will serve as the MAT ECHO Coordinator and assist with the HCV ECHO.



Alicia Huguelet, MRH, MSW, is the Director of Transformation at lowa PCA leading the performance improvement team in their work to assist health certers in implement process change, developing and strengthening programming and data tools to better manage work support programs.



Sarah Dixon, MPA, is a member of the lowa PCA's senior leadenhip team and currently servers as Senior Divector for Emerging Programs, She is responsible for leading the Association's response to members' needs in the areas of health care delivery system reforms and clinical, quality, bertomanace improvement, and transformation work. Sarah provides leadenship to the intestisciplinary transformation Collaborative team and the operations of lowateleaths*, a clinically integrated network of health centers in lows. Sarah also leads the development work and emerging programs for the PCA, many of which specifically focus on vulnerable populations, innovative partnerships and programming related to social determinants of health and assisting the health centers in lows to better connect to the needs of the communities they serve



Krist Roose, BA, CPHIMS, is the Technology Director of lowa PCA where she supports technology operations for the state-wide NIConcertCare Health Information Technology Network. Krist has over 20 years experience in Information Technology including 10+ years, in Health Information Technology. Krist is a Certifled Protessional of Health Information & Management Systems and received a Bachelor of Science degree in Management Information Systems and Finance from lows State University.



Des Moines University Continuing Medical Education provides the management and awarding of CME credits. The CMEstaff designated to this project include:

Vanessa Gray, MHA, CMP, CHCP Director, Continuing Medical Education







	Hepatitis C 101
	Initial Evaluation of Patients with HCV
Co	mmunity A Walgreens Specialty Pharmacy Program Overview
	Accessing Treatment for Un/Underinsured Patients
HC	V Treatment Medications Overview: What's New on the Market
	Treatment Considerations for People Living with HCV
	(re-infection; genotyping; people who use substances)
	Drug User Health and Person-Centered Language
	Treating Patients with Substance Use Disorders and HCV
	HIV and HCV Co-Infection Overview
	Populations Disproportionately Impacted by HCV and/or HIV
(LGBTQ+; Persor	ns experiencing human trafficking, intimate partner violence, homelessness; racial and ethnic groups)
	HCV Screening Among Pregnant Women
Chronic	Hepatitis C Treatment in Genotype 1 Patients WITHOUT Cirrhosis
	Extrahepatic Manifestations of Hepatitis C Virus Infection
Chronic Hep	atitis C Treatment in Genotype 1 Patients WITH Compensated Cirrhosis
	Interaction Considerations for Hepatitis C Genotype 1 Therapies
Monitoring Patier	nts Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
	House File 2377: Iowa's Opioid Act
	Alcohol Use Disorder Medications
	When HCV Treatment is Deferred
	Hepatitis C Epidemiology in Iowa
Sc	reening and Surveillance for Hepatocellular Carcinoma (HCC)
	Hepatitis B Overview
	Treatment Options for Chronic Hepatitis B
	Hepatitis C & B Co-Infection
	HIV Pre-Exposure Prophylaxis (PrEP)
	Non-Alcoholic Fatty Liver Disease (NAFLD)
	HIV Testing Overview
	Screening for Hemochromatosis
Health	Fconomics 101: Standard v. Enhanced Screening and Treatment





EASL HCV Guidelines: Drug and Alcohol Use, Incarceration Are Not Contraindications to HCV Therapy

- "PWIDs who are infected with HCV have an indication for antiviral therapy"
 - "DAA-based therapies are safe and effective in HCV-infected patients receiving OST, those with a history of injecting drug use, and those who recently injected drugs"
- "Excess alcohol should not preclude treatment"
 - "Patients with harmful alcohol consumption during treatment should receive additional support during antiviral therapy"
- "HCV treatment should be offered to HCV-infected patients in prison"

EASL HCV Guidelines: 2018

Slide credit: clinicaloptions.com

Components of PWID Care

"A combination of prevention strategies, including HCV treatment as prevention, are critical to substantially reduce HCV transmission and prevalence in these populations, especially in settings with high existing harm reduction coverage"

Harm Reduction and Care/Support Services

OST and overdose prevention Sterile needle/syringe programme

Peer support

Psychological care and social support

HCV/HIV screening and diagnosis

Antiviral therapy

Grebely. Nat Rev Gastroenterol Hepatol. 2017;14:641. Dillon. Hepatol Med Policy. 2016;1:2

Slide credit: clinicaloptions.com







Iowa HINTARY CARE ASSOCIATION				Iswa Primary Care Association			
	Hepatitis C Initial Pro	esent	ation Form				
Presentation Date	Sioustend Community	. Marrie Co	en Claire				
// / / / / / / / / / / / / / / / / / /			Cilincidii				
PLEASE NOTE that Project ECHO® C							
UNM-HSC clinician and any patient a patient in clinic. Sharing patient							
a patient in content starting patient	nome, minus or other racinglying	mjornic	tion violates /iii /or	privacy rows.			
Screening Encounter Date	require	d)					
= 00 50							
General Information/De	mographics						
Patient Name/ECHO ID:			Age:	59			
Gender:	Male Female		190				
Ethnicity - Hispanic or Latino:	□Yes ■No						
Race:	American Indian, Alaska Native Asian Black, African American Native Hawaiian, Pacific Islander White						
Insurance:	None Medicare Medicare Community Plan Commercial Health Insurance: Other:						
Suspected Route of HCV	Transmission (Check all	that a	pply)				
	on	Yes	Description				
Suspected Route of Transmission		[7]		rug Use in the last 12 months			
Suspected Route of Transmission Current or former injection drup	g user (even once)	_	□Yes No				
an and we are second or a			□les Mino				
Current or former injection drup	entrates made before 1987		☐ les ⊠uo				
Current or former injection drug Recipient of clotting factor cone Blood transfusion or solid organ Needlestick injury in healthcare	entrates made before 1987 transplant before July 1992 setting		Ties Mino				
Current or former injection drup Recipient of clotting factor cond Blood transfusion or solid organ	entrates made before 1987 transplant before July 1992 setting		Ties Muo				
Current or former injection drug Recipient of clotting factor cone Blood transfusion or solid organ Needlestick injury in healthcare	entrates made before 1987 transplant before July 1992 setting		Ties Muo				
Current or former injection drug Recipient of clotting factor cone Blood transfusion or solid organ Needlestick injury in healthcare Birth to an HCV-infected mothe	entrates made before 1987 I transplant before July 1992 settling r n items, such as razors or tooth		Ties Xino				
Current or former injection drug Recipient of clotting factor conc Blood transfusion or solid organ Needlestick injury in healthcare Birth to an HCV-infected mothe Sex with an HCV infected personal Sharing contaminated personal	entrates made before 1987 I transplant before July 1992 settling r n items, such as razors or tooth		Ties Muo				

		Yes	Description/Comments				
		1	Year of diagnosis: 2019				
		Any evidence of decompensation? Ascites Hepatic encephalopathy Variceal bleed					
Previous HCV Treatment			Year:Drug Regimen: Duration of treatment in weeks:				
Liver Biopsy			Year:Results:				
Hepatocellular Carcinoma			Year of diagnosis:				
Yes			Description/Comments				
	Type of disease:						
	Year:	Type of Cancer:					
		Type of Year:	Type of disease of the control of th				

completed the series.







Psychiatric D	iagnosis	Yes	Description							
Depression										
Anxiety			If yes, is patient on medication for anxiety? ☐Yes ■No							
Mania/Hypor	mania	☐ If yes, is patient on me				dication for Mania/F	ypomania?	□Yes □N	0	
Survey Sco	res									
PHQ-9 Score:	0				Date of sun	/ey: <u>5</u> /13 /2019				
Substance	Use History									
Substance Us	e History		Yes	No	Description	on/Comments				
Does patient currently drink alcohol?			V		If no, has the patient ever had a drinking problem? Yes No Date of last drink: 4 /3 /2019					
Does patient other than al	currently use dru cohol?	gs	V			piates timulants (cocaine, a enzodiazepines R larijuana A	mphetamine Hieret has Her wea	, etc.) d recen us of b	t relapse	
Does patient	smoke cigarettes	?	✓]	Ь	ut is k	ack on	track no	
Current M	edications: (P	lease	inclu	de	dosage)					
Medication Name Dos		sage		Frequency	Medication Nam	e	Dosage	Frequency		
atorvastatin 2		2	20 mg		q day					
lisinopril/hctz 20		/25 mg		q day						
				1						
				1						
Body Mass	Index									
Height:	71	71					□ Centimeters ■ Inches			
Weight:	227.5	227.5				□Kilograms	Poun	ds		
rreiBite.	24.04									

Laboratory

Basic Laboratories 4 /8 Date of Lab Draw: 1.0 Albumin 4.3 HGB 13.5 ALT 55 38.8 AST 40 266 55 Alk Phos **Platelets** 1.5 T. Bili Creatinine 0.2 Direct Bili Glucose 6.90 Total Prot Protime

Page 4 of 4

Other Essential Results	Date	Result
Fe		
TIBC	_/_/	
Ferritin		
Vitamin D 25-OH		_
AFP	4 / 8 / 2019	2.0
HIV Ab S	3 / 24 / 2019	NEG
HCV Genotype	4 / 8 / 2019	1a
HCV Viral Load	4 / 8 / 2019	345,814
Other: FIB-4 Score	5 / 16 /2019	1.20

For Clinical Calculators (APRI, MELD, etc.), visit: http://www.hepatitisc.uw.edu/page/clinical-calculators/meld


Please email the completed form to Julie Baker at jbaker@iowapca.org.






HCV ECHO HUB TEAM

- Donald Hillebrand, MD,
 - Medical Director, UnityPoint Health –
 Center for Liver Disease
- Steven Donnelly, PharmD
 - Community A Walgreens Specialty Pharmacy
- Mark Hillenbrand, LICSW
 - Authentic Freedom Counseling Center
- Megan Srinivas, MD,
 - Infectious Disease Community Health Centers of Fort Dodge
- Malissa S. Sprenger, MS, IAADC,
 - Coordinator Turning Point Treatment Center





https://www.hep-druginteractions.org/





JOIN THE HCV ECHO

- Learn how to treat HCV
- Get no cost CME credit
- · Meet lowa Medicaid prescribing requirements to allow PCPs to treat HCV patients

90-minute sessions every 3rd Tuesday of the month from 11:45 am - 1:15 pm | May 21 - December 2019

REGISTRATION

To register, email Julie Baker at jbaker@iowapca.org the following information:

- Name
- · Title
- Organization Name
- Email







UnityPoint Health Des Moines

Bringing
Specialty Liver Care
to
Patients
in their Communities






UnityPoint Health - Center for Liver Disease

Outreach Clinics

- Boone County Hospital (Boone)
- Story County Medical Center (Nevada)
- Clarke County Hospital (Osceola)
- UPH GI Clinic (Cedar Rapids)
- Grinnell Regional Medical Center (Grinnell)
- Trinity Regional Medical Center (Fort Dodge)
- Greater Regional Medical Center (Creston)

Telemedicine Services

- Clarke County (Osceola)*
- Greene County (Jefferson)



UnityPoint Health Des Moines Bringing Specialists to Your Communities

UPH Center for Liver Disease

Iowa PCA HCV ECHO

Outreach Clinics Telemedicine Clinics

Mentoring community providers in management of Chronic Hepatitis

- Mentorship & collaborative care of patients with liver disease
- Iowa Medicaid HCV Treatment Prior Authorization in collaboration with a specialist requirement



Iowa Harm Reduction Summit

Iowa HCV ECHO

Empowering providers to manage HCV in the community

Moving knowledge instead of patients

ECHO Coordinators

- Julie Baker,
 - Director of Preventive
 Services, Iowa Primary Care
 Association
 JBaker@iowapca.org
- Gagan Lamba,
 - Performance Improvement Manager Iowa Primary Care Association





